Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase.
about
Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.The dual topoisomerase inhibitor A35 preferentially and specially targets topoisomerase 2α by enhancing pre-strand and post-strand cleavage and inhibiting DNA religationPARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia.Sophoridinol derivative 05D induces tumor cells apoptosis by topoisomerase1-mediated DNA breakagePhase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid TumorsGenetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapies.Structure-based virtual screening toward the discovery of novel inhibitors of the DNA repair activity of the human apurinic/apyrimidinic endonuclease 1.PARP inhibitors as antitumor agents: a patent update (2013-2015).Clinical and cellular roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecanCHK1 and RAD51 activation after DNA damage is regulated via urokinase receptor/TLR4 signaling.Linker design for the modular assembly of multifunctional and targeted platinum(ii)-containing anticancer agents.PARPi potentiates with current conventional therapy in MLL leukemia.PARP inhibitors: Clinical utility and possibilities of overcoming resistance.On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site.
P2860
Q36544857-AFFFCDFF-066F-473C-804A-E5D1B3517907Q36545904-353FBE76-93D4-4A77-B12B-FC2C51D69104Q36685547-62FE4AD7-B7B8-4413-B2AC-9698AC4EBA89Q36908054-AF41ABAA-6EF5-408C-B349-438FD54119C4Q37059846-7173D094-02C4-40AE-BE81-4FB5A371EBA0Q37317404-4E7E292B-8CD4-4387-9017-75478E7B49DAQ38733657-EFC1C4D2-06D2-4E70-8E19-A772FF3BA629Q38795712-338A44C7-590E-4528-A920-B35C72FEBBBCQ38927275-A3D67575-5E57-4F9A-AA04-DEECB544E443Q41432461-42B4F338-0D6C-4FE9-95A4-277303721D9CQ41738179-3F683ACD-C437-4D27-8A70-828421657087Q47833710-4E4F2DA5-0E9E-48A2-955D-5377C36006A0Q50076626-64F0BAB6-4F9A-4A2D-BDCC-F584BA461A4CQ55054276-52B7176A-1C1B-47E5-B3DC-7CDFB1DDEAFB
P2860
Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Preferential potentiation of t ...... by PARP inhibition in S phase.
@en
Preferential potentiation of t ...... by PARP inhibition in S phase.
@nl
type
label
Preferential potentiation of t ...... by PARP inhibition in S phase.
@en
Preferential potentiation of t ...... by PARP inhibition in S phase.
@nl
prefLabel
Preferential potentiation of t ...... by PARP inhibition in S phase.
@en
Preferential potentiation of t ...... by PARP inhibition in S phase.
@nl
P2860
P356
P1476
Preferential potentiation of t ...... by PARP inhibition in S phase
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2014.378
P407
P577
2014-07-08T00:00:00Z